Meeting
2016 ASCO Annual Meeting
ESOPEC: A prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy to neoadjuvant chemoradiation in patients with adenocarcinoma of the esophagus (NCT02509286).
Authors
Jens Hoeppner
University of Freiburg - Medical Center, Freiburg, Germany
Jens Hoeppner , Florian Lordick , Thomas B. Brunner , Torben Glatz , Claudia Schmoor , Dietmar Lorenz , Christian Ell , Joerg Ruediger Siewert , Ulrich Theodor Hopt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02509286
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS4131)
DOI
10.1200/JCO.2016.34.15_suppl.TPS4131
Abstract #
TPS4131
Poster Bd #
123a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.
First Author: James Tankel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.
First Author: Mark R. Middleton
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian